公开资料显示，金丹科技是一家以玉米为核心原料，依托现代微生物发酵技术生产乳酸的国家高新技术 企业。 （文章来源：证券日报） 公告显示，金丹科技此次员工持股计划的业绩考核分为公司层面业绩考核和个人层面绩效考核，考核年 度为2026年和2027年两个会计年度。在公司层面，以2025年为基数，2026年该公司营业收入增长不低于 10%或净利润增长不低于20%；2027年该公司营业收入增长不低于30%或净利润增长不低于30%。 金丹科技表示，公司目前正处于发展的战略窗口期和关键期，此次员工持股计划旨在进一步建立、健全 激励机制，吸引和留住优秀人才，充分调动员工的积极性和创造力，提高员工的凝聚力和公司核心竞争 力，促进公司的可持续增长。 本报讯 （记者肖艳青）11月24日晚间，河南金丹乳酸科技股份有限公司（以下简称"金丹科技"）发布 第一期员工持股计划（草案），该计划对象为对该公司整体业绩和中长期发展具有重要作用和影响的公 司（含子公司）董事、高级管理人员、核心管理人员、核心技术（业务）人员，总人数不超过147人。 此员工持股计划的股份来源为该公司回购的股份，受让的股票规模合计不超过100万股，拟受让价格为 11.12 ...

11月18日，金丹科技盘中下跌2.00%，截至14:26，报18.60元/股，成交8187.03万元，换手率2.75%，总 市值42.27亿元。 金丹科技所属申万行业为：基础化工-化学制品-食品及饲料添加剂。所属概念板块包括：可降解、小 盘、土地流转、新材料等。 截至9月30日，金丹科技股东户数2.02万，较上期减少9.31%；人均流通股7830股，较上期增加16.34%。 2025年1月-9月，金丹科技实现营业收入12.04亿元，同比增长8.41%；归母净利润1.32亿元，同比增长 30.06%。 分红方面，金丹科技A股上市后累计派现8401.33万元。近三年，累计派现4788.24万元。 责任编辑：小浪快报 资金流向方面，主力资金净流出862.82万元，特大单买入227.92万元，占比2.78%，卖出220.70万元，占 比2.70%；大单买入974.17万元，占比11.90%，卖出1844.21万元，占比22.53%。 金丹科技今年以来股价跌0.75%，近5个交易日跌2.46%，近20日涨4.03%，近60日跌2.36%。 资料显示，河南金丹乳酸科技股份有限公司位于河南省周口市郸城县金丹大道08号，成立 ...

Core Insights - Recent research indicates that autophagy is activated during exercise, mediating the health benefits associated with physical activity. However, the molecular mechanisms regulating skeletal muscle autophagy during exercise remain unclear [3][5]. Group 1: Research Findings - A study published in Cell Chemical Biology reveals that lactate produced during exercise enhances autophagy in skeletal muscle by lactylation of the mTOR protein [3][5]. - Lactate is identified as a positive regulator of autophagy in muscle cells, with levels rapidly increasing after a single exercise session [5]. - The study demonstrates that lactate promotes lactylation at the K921 site of the mTOR protein, inhibiting mTORC1 activity and enhancing autophagy [5][8]. Group 2: Implications - This research fundamentally redefines lactate, transforming it from a mere metabolic byproduct into a key signaling molecule that mediates exercise-induced skeletal muscle adaptation [7][8]. - The findings provide a conceptual framework for understanding how muscle metabolism translates into adaptive responses, opening new avenues for the treatment of muscle and metabolic diseases [8].

Core Viewpoint - The company, Jindan Technology, currently has no business dealings with NVIDIA and will disclose any significant future developments in accordance with information disclosure regulations [1] Company Overview - Jindan Technology (300829.SZ) is a national high-tech enterprise that primarily uses corn as a core raw material to produce lactic acid through modern microbial fermentation technology [1] - The main products include lactic acid and its derivatives such as sodium lactate and calcium lactate [1] Product Applications - Lactic acid, a naturally occurring organic acid in the human body, has good biocompatibility and is widely used in various fields including food, feed, biodegradable materials, industry, and pharmaceuticals [1] Future Outlook - The company will continue to monitor technological trends and market opportunities in the upstream and downstream of the industry chain [1] - Any significant business progress in the future will be announced in a timely manner as per disclosure rules [1]

近日，21财经《辟谣财知道》注意到，市场上有消息称，蒋栋梁其团队研发15年的玉米基可降解骨钉技 术，打破国外垄断，具有国际领先水平，无需二次手术即可在体内降解为二氧化碳和水，硬度媲美金属 且无毒无害。获相关媒体报道，该技术已在周口实现产业化应用。蒋栋梁是河南金丹乳酸科技股份有限 公司技术总监，专注玉米精深加工领域研究。 11月13日，金丹科技（300829.SZ）回应称，上述报道内容未经公司确认，不符合公司当前的实际情 况，公司已经与相关媒体进行沟通并要求更正。关于公司技术研发信息，请以公司官网和对外公告内容 为准。 21财经·南财快讯记者以投资者身份致电金丹科技，公司证券部工作人员进一步指出，目前公司聚乳酸 项目仍在建："公司年产7.5万吨聚乳酸项目正在建设中，预计明年6月份建成，若试车后产品达到预期 标准，可能就会直接进行量产了。"至于项目建好后，是否会将聚乳酸应用在骨钉产品开发方面，董事 会方面暂未作出决策。对于蒋栋梁身份，前述工作人员确认其为公司技术总监。 公开资料显示，金丹科技主营业务为研发、生产、销售乳酸及其系列产品，主要产品是乳酸、乳酸盐、 副产品。该公司经过多年的发展目前已成为中国乳酸行业的龙 ...

Core Viewpoint - The article emphasizes the importance of biomass conversion and utilization due to challenges such as resource depletion and environmental pollution, highlighting the complexity of biomass composition and structure, which necessitates graded conversion methods for effective chemical production [2]. Biomass Conversion Strategies - The article discusses the implementation of graded strategies for biomass conversion, focusing on hemicellulose, cellulose, and lignin. These strategies enable the production of platform compounds like HMF and lactic acid, with a particular emphasis on achieving high stereoselectivity for chiral lactic acid and hydroxyacetic acid [3]. - The lignin priority strategy allows for the production of phenolic compounds and lignin-based materials, including structural color materials [3]. Research Contributions - Professor Hu Changwei's team at Sichuan University has conducted extensive research on the effective utilization of biomass resources, resulting in high-value products such as D-lactic acid, FDCA, furfural, high optical purity D-glyceric acid, biomass liquid fuels, and lignin structural color materials [3]. - Professor Hu will present a report titled "Research on the Preparation of High-Value Chemicals from Graded Conversion of Biomass" at the 2025 Non-Food Biomass High-Value Utilization Forum [3]. Forum Information - The 2025 Non-Food Biomass High-Value Utilization Forum will take place from November 27-29 in Hangzhou, featuring 50 reports and participation from industry experts [8]. - Keynote speakers include prominent figures from Zhejiang University and various research institutions, discussing innovations in biomass utilization and related technologies [8][9].

每经AI快讯，有投资者在投资者互动平台提问：今年前三季度，公司产品销售增量，主要来自下游哪 些应用领域？ 金丹科技（300829.SZ）11月5日在投资者互动平台表示，公司前三季度销量的增加主要是国内PLA产能 逐步释放拉动了乳酸市场需求，同时，食品饮料及海外出口也构成公司销量增加的支撑点。 （文章来源：每日经济新闻） ...

Core Insights - The article discusses the recent developments in the biomanufacturing industry, particularly focusing on projects related to lactic acid and polylactic acid production in Shandong province, China [2][3][4][5]. Project Developments - The Pingyi Fengyuan Lactic Acid Biotechnology Co., Ltd. is set to invest 60 million yuan in a project to produce 90,000 tons per year of lactic acid, utilizing straw sugar through fermentation and purification processes [3]. - The Pingyi Fengyuan Polylactic Acid Biotechnology Co., Ltd. plans to establish a project with a production capacity of 60,000 tons per year of polylactic acid, using lactic acid as a raw material [5]. - The Pingyi Polylactic Acid Modified Materials Co., Ltd. will invest 15 million yuan in a project to produce 60,000 tons per year of modified polylactic acid, with an expected completion date in January 2026 [6]. Production Capacity and Investment - The lactic acid project will have a production line capable of achieving an annual output of 90,000 tons, while the polylactic acid and modified materials projects will each reach 60,000 tons per year upon completion [3][5][6]. - The total investment for the modified materials project includes 1 million yuan allocated for environmental protection measures [6]. Industry Events - The Fifth Non-Grain Biomass High-Value Utilization Forum will focus on non-grain bio-based chemicals and materials, highlighting the industry's commitment to sustainable practices [9][10]. - The forum will feature various specialized sessions, including discussions on bio-based chemicals and materials, indicating a growing interest in the sector [13].

Core Viewpoint - The research reveals a novel metabolic interaction between tumor-associated macrophages (TAM) and hepatocellular carcinoma (HCC) cells, identifying TAM as a source of acetate that drives HCC metastasis through the synthesis of acetyl-CoA [2][3][4]. Group 1: Research Findings - TAM secretes acetate, which is then taken up by HCC cells to support their acetate accumulation [3]. - Lactate produced by HCC cells activates lipid peroxidation-ALDH2 pathways in TAM, promoting the secretion of acetate [3]. - In a mouse model of HCC, knocking out the ALDH2 gene in TAM reduces acetate levels in HCC cells and decreases lung metastasis of HCC [3][4]. Group 2: Implications - The study positions TAM as a critical acetate supply source that drives HCC metastasis, suggesting potential intervention targets in the tumor microenvironment [2][4].

Group 1 - The core viewpoint of the news is that Jindan Technology's stock has experienced a decline in price and trading activity, with a notable drop in net outflow of funds and a decrease in stock price over various time frames [1][2] - As of October 16, Jindan Technology's stock price was 17.78 yuan per share, with a market capitalization of 4.041 billion yuan [1] - The company has seen a year-to-date stock price decrease of 5.13%, a 3.00% drop over the last five trading days, and a 12.76% decline over the last 20 days, while experiencing a 3.37% increase over the last 60 days [1] Group 2 - Jindan Technology reported a revenue of 777 million yuan for the first half of 2025, reflecting a year-on-year growth of 5.43%, and a net profit attributable to shareholders of 95.796 million yuan, which is a 56.31% increase year-on-year [2] - The company has a total of 22,300 shareholders as of June 30, which is an increase of 38.71% compared to the previous period, while the average number of circulating shares per shareholder decreased by 18.17% to 6,730 shares [2] - Since its A-share listing, Jindan Technology has distributed a total of 840.133 million yuan in dividends, with 478.824 million yuan distributed over the past three years [2]